Inhibition of Factor Xa
- 1 January 2005
- journal article
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 5 (5) , 279-290
Abstract
Anticoagulant therapy plays an important role in the prevention and treatment of pathologic arterial and venous thrombosis. There is increasing enthusiasm in the inhibition of Factor Xa as a target to achieve therapeutic anticoagulation because of its central and ‘upstream’ position in the coagulation process. The indirect, selective, parenteral Factor Xa inhibitor fondaparinux sodium (synthetic pentasaccharide) has been studied extensively in the prevention and treatment of venous thromboembolism. In an overview of four studies in patients undergoing major orthopedic surgery, fondaparinux sodium was associated with a 55% reduction in recurrent thromboembolism, albeit with a modest increase in bleeding. Preliminary results from phase II studies of fondaparinux sodium in patients with ST-elevation and non-ST-elevation acute coronary syndromes have been promising and have led to the initiation of two large phase III trials, which are currently underway. Idraparinux sodium, a long-acting synthetic pentasaccharide, is currently being investigated as a once-weekly alternative to other long-term anticoagulants. DX-9065a and razaxaban are two of many direct selective Factor Xa inhibitors currently in development. DX-9065a has been studied in phase II trials in patients undergoing percutaneous coronary intervention and in those with non-ST-elevation acute coronary syndromes. Razaxaban has been studied in a phase II trial in patients who have undergone orthopedic surgery. Data from these trials, although preliminary and based on small numbers of patients, suggest that direct selective Factor Xa inhibition may provide effective anticoagulation, perhaps without excessive bleeding. Inhibition of Factor Xa is a promising target for the prevention and treatment of thrombosis in both the venous and arterial circulation. Ongoing investigation with numerous oral and parenteral inhibitors of Factor Xa will establish the potential of Factor Xa as a target for therapeutic anticoagulation.Keywords
This publication has 43 references indexed in Scilit:
- Hereditary and Acquired Antithrombin DeficiencySeminars in Thrombosis and Hemostasis, 1999
- Vascular-Bed–Specific Hemostasis and Hypercoagulable StatesNew England Journal of Medicine, 1999
- Thrombin Generation, Inhibition and Clinical Outcomes in Patients With Acute Myocardial Infarction Treated With Thrombolytic Therapy and Heparin: Results From the GUSTO-I Trial fn1fn1This study was supported by Genentech, Inc., South San Francisco, California; Bayer Corporation, New York, New York; CIBA-Corning, Medfield, Massachusetts; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.JACC, 1998
- Low-Molecular-Weight HeparinsNew England Journal of Medicine, 1997
- Kinetics of Human Factor VII ActivationBiochemistry, 1996
- Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated HeparinNew England Journal of Medicine, 1995
- Oral Anticoagulant DrugsNew England Journal of Medicine, 1991
- HeparinNew England Journal of Medicine, 1991
- Anticoagulantly active heparin-like molecules from vascular tissueBiochemistry, 1984
- Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin.Proceedings of the National Academy of Sciences, 1980